Management

Ascelia Pharma has an experienced management team:

Magnus Corfitzen
Magnus Corfitzen

Born 1975. Chief Executive Officer since 2014.

Professional background
Magnus Corfitzen has extensive experience from investing, building and growing Life Science companies in various roles including operational activities or investment responsibilities for public and private biotech and medtech companies. Magnus Corfitzen also has board experience from a number of Life Science companies. Magnus Corfitzen has previously inter alia been Investment Director at Sunstone Capital A/S and Investment Director at Vækstfonden (the Danish Growth Fund). Prior to entering the healthcare venture capital field he was a Portfolio Manager at Danske Capital with responsibility for investments into listed biotech and medtech companies and he started his career at McKinsey & Company.
Education
M.Sc. in Mathematical Economics from the University of Aarhus, Denmark, which included studies at Harvard University, US.
Other ongoing assignments
Board member of Ascelia Inventive AB. CEO of Oncoral Pharma ApS.
Holdings in Ascelia
27,180 shares and 458,856 employee stock options in Ascelia Pharma AB. Magnus Corfitzen also holds approximately 2 per cent of the shares in CMC SPV of 3 April 2017 AB that holds 2,937,606 shares in Ascelia Pharma AB.
Carl Bjartmar
Carl Bjartmar

Born 1963. Chief Medical Officer since 2018.

Professional background
Carl Bjartmar has a long and solid track record in late-stage orphan drug development. He has previously served in senior roles at large international pharma companies such as Lundbeck, Sanofi and Genzyme, where he gained extensive experience in clinical development, in particular the development of novel therapies for rare diseases. Carl was most recently before joining Ascelia, Chief Medical Officer for the Swedish biotech company Wilson Therapeutics.
Education
M.D. and Ph.D. from the University of Linköping.

Other ongoing assignments
-
Holdings in Ascelia
17,000 shares and 153,059 employee stock options in Ascelia Pharma AB.
Kristian Borbos
Kristian Borbos

Born 1978. Chief Financial Officer since 2017.

Professional background
Kristian Borbos has extensive banking and finance experience from large listed companies as Sell-side Analyst and other advisory roles in banking to various financial positions in large corporates including treasury, financial reporting and planning and IR activities. Kristian Borbos has previously inter alia been Business Finance Manager at Novozymes, Lead Investor Relations Manager at DONG Energy and senior analyst at Danske Bank and Danske Markets.
Education
M.Sc. in Business Administration from Lund University, Sweden.
Other ongoing assignments
Deputy board member of Ascelia Incentive AB.
Holdings in Ascelia
3,400 shares and 153,059 employee stock options in Ascelia Pharma AB.
Dorthe da Graça Thrige
Dorthe da Graça Thrige

Born 1967. Chief Operating Officer since 2014.

Professional background
Dorthe da Graça Thrige has extensive experience in R&D and executive management at leading Swedish and Danish biotech and pharma companies such as Pharmacia, AstraZeneca and Active Biotech. Dorthe da Graça Thrige has previous experience from inter alia various positions at Active Biotech AB, including Director of Development, Head of Project Management and Head of Drug Discovery and Research Scientist at AstraZeneca.
Education
M.Sc. in Pharmaceutical Sciences and Ph.D. in Structural Medicinal Chemistry from University of Copenhagen, Denmark.

Other ongoing assignments
-
Holdings in Ascelia
15,530 shares and 152,898 employee stock options in Ascelia Pharma AB. Dorthe da Graça Thrige also holds approximately 1 per cent of the shares in CMC SPV of 3 April 2017 AB that holds 2,937,606 shares in Ascelia.
Mikael Widell - Ascelia Pharma
Mikael Widell
Mikael Widell

Born 1958. Head of IR & Communication since 2018.

Professional background
Mikael Widell has more than 30 years’ experience within communications, including journalism with 14 years within financial media, e.g. Dagens Industri, and has had different positions within in-house corporate communications, e.g. AstraZeneca, Biovitrum (Sobi) and Nordic Capital as well as strategic work as a communications advisor within financial PR and IR. Mikael is a partner and co-founder of the IR/PR firm Cord Communications and is Head of Communication & IR at the main market listed company Calliditas Therapeutics.
Education
M.A. in English from Lund University and studies in Economics at Lund University.
Other ongoing assignments
Board member of CordCom Consultants AB. General partner of WZ Kommunikation Kommanditbolag.
Holdings in Ascelia
-

Mangoral

Our lead candidate Mangoral is a liver imaging drug (i.e. a liver specific contrast agent) being developed for detection and localization of potential liver metastases, using Magnetic Resonance Imaging (“MRI”) in patients where use of the current gold standard gadolinium-based contrast agents (“GBCAs”) may be medically inadvisable or cannot be administered. Mangoral is currently ready for Phase III clinical development.

Oncoral

Oncoral is a novel tablet-based formulation of the well-known chemotherapeutic agent irinotecan, intended for the treatment of advanced gastric (stomach) cancer. Irinotecan is today mainly used for treating metastasized colorectal cancer. Although irinotecan is currently not approved for treating gastric cancer in the United States and in the EU, there is off-label use for this indication. Oncoral is currently being evaluated in an investigator sponsored Phase I study.

DEVELOPMENT PLAN

Ascelia has established a development program for lead candidate Mangoral, consisting of a pivotal Phase III efficacy study and two supportive studies. The clinical development strategy for Oncoral, Ascelia´s second drug candidate, is to obtain Phase II data and then to partner for the further development.